20-F: Can-Fite BioPharma Reports Financial Results for Fiscal Year 2023

Can-Fite BioPharma's 20-F filing highlights its clinical-stage biopharmaceutical focus, A3AR platform, and ongoing development of Piclidenoson and Namodenoson, while acknowledging continued operating losses and the need for additional capital.

Summary

• Can-Fite BioPharma is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics.
• The company's primary focus is on cancer, liver, and inflammatory diseases, utilizing the A3 adenosine receptor (A3AR) as a therapeutic target.
• Key drug candidates include Piclidenoson (CF101) for psoriasis and Namodenoson (CF102) for HCC and NASH.
• The company has incurred operating losses since its inception in 1994, with net losses of $7.6 million in 2023, $10.1 million in 2022, and $12.6 million in 2021.
• As of December 31, 2023, the company had an accumulated deficit of approximately $158.5 million.
• Can-Fite believes its existing financial resources will be sufficient to meet its requirements for the next twelve months.
• The company anticipates the need to raise additional capital to fund ongoing and future clinical trials and commercialization efforts.
• Can-Fite's strategy involves partnering with pharmaceutical companies and out-licensing its product candidates.
• The company faces risks related to clinical trial outcomes, regulatory approvals, competition, and intellectual property protection.
• Political, economic, and military instability in Israel, where the company is headquartered, could adversely affect its operations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing clinical trials and strategic partnerships, the company's history of operating losses and the need for additional capital raise concerns.

Positives

• Piclidenoson has shown a favorable safety profile and significant anti-inflammatory effects in clinical studies.
• Namodenoson has demonstrated anti-cancer, anti-viral, and liver-protective effects in pre-clinical and clinical studies.
• The company has orphan drug designation for Namodenoson in the treatment of HCC in the US and Europe.
• Can-Fite has established partnerships with pharmaceutical companies for the development and commercialization of its drug candidates.
• The company is developing formulations of cannabis components for the treatment of diseases in which there is an overexpression of A3AR.

Negatives

• The company has a history of operating losses and an accumulated deficit of $158.5 million as of December 31, 2023.
• Can-Fite has not yet commercialized any products or generated any revenues from product sales.
• The company is dependent on raising additional capital to fund its operations and clinical trials.
• Clinical trials are expensive, time-consuming, and subject to regulatory requirements and potential delays.
• The company faces significant competition from larger pharmaceutical and biotechnology companies.
• The expiry of a patent that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we had by virtue of this license may diminish our proprietary position.

Risks

• The company's product candidates may not receive regulatory approval or achieve commercial success.
• Clinical trial results may not be predictive of later-stage trial outcomes.
• The company may be unable to establish and maintain strategic partnerships.
• Can-Fite's operations in Israel are subject to political, economic, and military instability in the region.
• The company may not be able to protect its intellectual property rights.
• The company may not satisfy the NYSE American requirements for continued listing.

Future Outlook

Can-Fite believes its existing financial resources will be sufficient to meet its requirements for the next twelve months, but anticipates the need to raise additional capital to fund ongoing and future clinical trials and commercialization efforts.

Industry Context

The announcement highlights Can-Fite's position in the competitive biopharmaceutical industry, specifically in the psoriasis, HCC, and NASH therapeutic areas, where it faces competition from major pharmaceutical companies.

Comparison to Industry Standards

• The document mentions competitors in the psoriasis therapeutic field including Amgen, J&J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB and more.
• Competitors in the HCC field include companies such as Bayer, Exelixis, Merck, Roche, Eisai, Astrazenca, Beigene, Novartis, and Bristol-Myers Squibb.
• Competitors in the nonalcoholic steatohepatisi, or NASH, field (also known as metabolic dysfunction-associated steatohepatitis, or MASH)) include companies such as Gilead, Genfit, Galmed, Madrigal, Akero, 89Bio, Viking, and Terns.
• Competitors in the erectile dysfunction field include Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals.

Related Party Transactions

• One of the Companys directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters (the Service Provider).
• The Service Provider charges the Company for services it renders on an hourly basis.
• Ms. Harpaz is the daughter of Pnina Fishman.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• The company's ability to develop and commercialize its product candidates will impact its employees, customers, and suppliers.
• Creditors face risks related to the company's ability to repay its obligations.

Next Steps

• Commencement of pivotal Phase III studies for Piclidenoson in the treatment of psoriasis is expected in the second half of 2024.
• The company is conducting a pivotal Phase III trial for Namodenoson in the treatment of advanced liver cancer.
• Can-Fite is conducting a Phase IIb study of Namodenoson in the treatment of NASH.
• Preparatory work is underway for a Phase IIa study with Namodenoson for the treatment of pancreatic cancer.
• The company is investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction.
• Can-Fite is conducting pre-clinical studies with formulations of cannabis components for the treatment of diseases in which there is an overexpression of A3AR.

Key Dates

Keywords

Piclidenoson, Namodenoson, A3AR, clinical trials, biopharmaceutical, HCC, NASH, psoriasis, Can-Fite, FDA